development of major gastroduodenal diseases , such as peptic ulcers and gastric cancer

The resistance of Helicobacter pylori strains to clarithromycin is increasing in several developed countries and their association with a genetic pattern circulation has been variously explained as related to different geographical areas. In this study we have reported: the prevalence of the resistance of H. pylori, isolated in Sicily, to clarithromycin; the principal point of mutation associated with this resistance; and the more frequent association between resistance to clarithromycin and cagA, the EPIYA motif, and the vacA and oipA genes. Resistance to clarithromycin was detected in 25 % of cases, the main genetic mutation involved being A2143G. The cagA gene was present in 48 % of cases and the distribution of the EPIYA motif was: ABC in 35 cases; ABCC in 8 cases; ABCCC in 2 cases; ABC-ABCC in 2 cases; and ABC-ABCC-ABCCC in 1 case. Regarding the vacA allele, an s1i1m1 combination was detected in 35 % of cases, s1i1m2 in 12 %, s1i2m2 in 12 %, s2i2m2 in 40 %, and a double s1m1-m2 mosaic in 1 % of cases. The status of the oipA gene was ‘off’ in 45 % of cases and ‘on’ in 55 %. Resistance to clarithromycin was found to be high in Sicily, but no correlation was found among resistance to clarithromycin, the vacA gene and oipA status; a higher correlation was observed between resistant strains and cagA-negative strains. Received 5 January 2015 Accepted 29 August 2015

[1]  A. Abadi,et al.  Helicobacter pylori vacA as Marker for Gastric Cancer and Gastroduodenal Diseases: One but Not the Only Factor , 2014, Journal of Clinical Microbiology.

[2]  Y. Yamaoka,et al.  Virulence genes of Helicobacter pylori in gastritis, peptic ulcer and gastric cancer in Laos. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[3]  F. Bazzoli,et al.  Epidemiology of Helicobacter pylori Infection , 2014, Helicobacter.

[4]  J. Gisbert,et al.  Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. , 2014, World journal of gastroenterology.

[5]  A. Zullo,et al.  Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? , 2013, World journal of gastrointestinal pathophysiology.

[6]  A. Zullo,et al.  High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. , 2012, Journal of gastrointestinal and liver diseases : JGLD.

[7]  J. Huebner,et al.  Influence of a 23S ribosomal RNA mutation in Helicobacter pylori strains on the in vitro synergistic effect of clarithromycin and amoxicillin , 2012, BMC Research Notes.

[8]  H. Goossens,et al.  Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption , 2012, Gut.

[9]  Gian Franco Gensini,et al.  Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.

[10]  C. Hassan,et al.  Worldwide H. pylori antibiotic resistance: a systematic review. , 2010, Journal of gastrointestinal and liver diseases : JGLD.

[11]  S. Cardoso,et al.  High Prevalence of Clarithromycin Resistance and cagA, vacA, iceA2, and babA2 Genotypes of Helicobacter pylori in Brazilian Children , 2010, Journal of Clinical Microbiology.

[12]  G. Perez-Perez,et al.  High Prevalence of Clarithromycin-Resistant Helicobacter pylori Strains and Risk Factors Associated with Resistance in Madrid, Spain , 2010, Journal of Clinical Microbiology.

[13]  M. Alfaresi,et al.  Characterization of clarithromycin resistance in isolates of Helicobacter pylori from the UAE , 2010, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[14]  S. Chaussade,et al.  High Level of Antimicrobial Resistance in French Helicobacter pylori Isolates , 2010, Helicobacter.

[15]  C. Hassan,et al.  Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. , 2010, The Journal of antimicrobial chemotherapy.

[16]  I. Mitov,et al.  Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents , 2010, Expert review of anti-infective therapy.

[17]  A. Zullo,et al.  Minimal inhibitory concentration (MIC) values and different point mutations in the 23S rRNA gene for clarithromycin resistance in Helicobacter pylori. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[18]  A. Gullo,et al.  Prevalence of virulence-associated genotypes of Helicobacter pylori and correlation with severity of gastric pathology in patients from western Sicily, Italy , 2009, European Journal of Clinical Microbiology & Infectious Diseases.

[19]  Nayoung Kim,et al.  Gene mutations of 23S rRNA associated with clarithromycin resistance in Helicobacter pylori strains isolated from Korean patients. , 2008, Journal of microbiology and biotechnology.

[20]  D. Merrell,et al.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori. , 2008, Current drug therapy.

[21]  M. Mohagheghi,et al.  A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. , 2007, Gastroenterology.

[22]  D. Sgouras,et al.  Strategy To Characterize the Number and Type of Repeating EPIYA Phosphorylation Motifs in the Carboxyl Terminus of CagA Protein in Helicobacter pylori Clinical Isolates , 2006, Journal of Clinical Microbiology.

[23]  C. Hassan,et al.  Claritromycin resistance and Helicobacter pylori genotypes in Italy. , 2006, Journal of microbiology.

[24]  E. Kuipers,et al.  Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. , 2006, The Lancet. Infectious diseases.

[25]  H. Higashi,et al.  Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis , 2005, Cancer science.

[26]  Ahmed A. Majeed,et al.  Comparative genomics of Helicobacter pylori isolates recovered from ulcer disease patients in England , 2005, BMC Microbiology.

[27]  J. Atherton,et al.  Simple Method for Determination of the Number of Helicobacter pylori CagA Variable-Region EPIYA Tyrosine Phosphorylation Motifs by PCR , 2005, Journal of Clinical Microbiology.

[28]  D. Graham,et al.  Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. , 2002, Gastroenterology.

[29]  L. van Doorn,et al.  Importance of Helicobacter pylori cagA and vacAstatus for the efficacy of antibiotic treatment , 2000, Gut.

[30]  S. Bhakdi,et al.  vacA Genotypes and Genetic Diversity in Clinical Isolates of Helicobacter pylori , 1998, Clinical Diagnostic Laboratory Immunology.

[31]  D. Taylor,et al.  Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations , 1997, Antimicrobial agents and chemotherapy.

[32]  M. Blaser,et al.  Mosaicism in Vacuolating Cytotoxin Alleles of Helicobacter pylori , 1995, The Journal of Biological Chemistry.

[33]  M. Catalano,et al.  Helicobacter pylori oipA, vacA and dupA genetic diversity in individual hosts. , 2010, Journal of medical microbiology.